PharmaForce International: Majority of Physicians Say They Feel "Somewhat" or "Very" Comfortable in Prescribing a Biosimilar in Place of a Traditional Biologic

READING, Pa., Aug. 1, 2017 /PRNewswire/ -- In an effort to gain a comprehensive understanding of the biosimilars marketplace, PFI interviewed personnel across multiple business functions including sales, marketing, strategy, medical affairs, market access, and reimbursement.

Lorrie Berg-Henne, Director of Marketing and Sales at PFI, says that awareness among physicians has risen over the past 2-3 years.

"Early adopter physicians who stay current with the medical literature, who take online CME courses, and who attend conferences are usually well aware of biosimilars," Berg-Henne said.

"However, there are a large number of 'wait and see' physicians who still remain relatively unaware of biosimilars, thus lowering the chance of these medicines being prescribed to patients."

Additional industry insight captured in this report will allow commercial pharmaceutical professionals to:

1. Fine-tune their own biosimilar commercial operations initiatives by reviewing perceptions among physicians and payers
2. Gain an understanding of hurdles to biosimilar market entry
3. Understand the role of an effective managed care effort on biosimilar commercialization
4. Discover the effect of discounting on biosimilar sales models
5. See observed variations in biosimilar uptake across therapeutic areas

For more information on the report mentioned above, please contact Colton Dunkle at [email protected] or by phone at 610-370-0603.

PharmaForce International (PFI) is a competitive intelligence firm with over two decades of experience in the pharmaceutical and biotech industries. PFI has become the market leader in commercial operations benchmarking and competitive intelligence. The globally focused company employs marketplace experts uniquely qualified to perform primary research required by clients in most major pharmaceutical markets around the world, including Europe, India, Japan, Latin America, and the United States.

SOURCE PharmaForce International